Revolution Medicines just woke up biotech

What happened

Daraxonrasib rewrites the standard of care in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is the single worst common cancer in oncology. Median overall survival in second-line metastatic disease has been stuck at 6-7 months for over two decades, despite dozens of failed trials. The disease is driven by KRAS mutations in >90% of cases. KRAS is a faulty "on/off switch" inside the cell that, when broken, tells tumors to keep growing and for decades it has been considered "undruggable" because its surface offered no good place for a drug to bind. 

On April 13, 2026, Revolution Medicines reported the topline results of RASolute 302, a pivotal Phase 3 trial in previously treated metastatic PDAC patients. The results:

• Median overall survival: 13.2 months vs. 6.7 months (on chemotherapy)
• Hazard ratio: 0.40, p<0.0001, meaning a 60% reduction in the risk of death

This is the first meaningful survival gain in pancreatic cancer in decades. The stock surged 41% on the day, adding ~$5.6B to its market cap in a single session. 

A $2bn raise that validates and funds a platform 

Two days later, Revolution Medicines announced and priced a $2bn concurrent offering:

• $1.5bn common stock at $142 per share (upsized from $750mn)
• $500mn convertible senior notes due 2033 at 0.50%, with a conversion price of ~$199 (40% premium)

This is arguably the largest-ever follow-on raise for a pre-revenue biotech. The previous ceiling for clinical-stage biotechs sat around $500mn–$1bn. Comparable or larger raises historically came either from commercial-stage pharma (Regeneron Pharmaceuticals Inc, Vertex Pharmaceuticals, Gilead Sciences secondaries) or from COVID-vaccine names riding a unique one-off tailwind. For a pre-revenue, pre-commercial oncology asset to pull $2bn in a single shot is unprecedented.

Combined with the $2bn non-dilutive synthetic royalty deal signed with Royalty Pharma in mid-2025, Revolution Medicines now has roughly $6bn in accessible capital, positioning it to self-fund through the commercialization of daraxonrasib and simultaneously advance a pipeline of eight Phase 3 trials.

Impact on our Investment Case

Revolution Medicines was the top position in our Biotech 360° portfolio ahead of this readout. We initiated the position on 27 June 2024 at ~$40 on conviction in the RAS(ON) active-state mechanism, and reinforced it on 25 November 2025 at ~$65 ahead of the pivotal readout.

The RAS(ON) platform is now de-risked

Our thesis on Revolution Medicines has always been that targeting KRAS in its active state, when the protein is actually switched on and driving the cancer, works better than the "OFF"-state approach taken by Amgen (sotorasib) and Mirati/ BMS (adagrasib). Those earlier drugs showed real responses, but tumors quickly found ways around them and resistance set in.

Daraxonrasib's pancreatic cancer data show that the ON-state approach works and, crucially, across many different KRAS mutations, not just one. The implication: the same platform should deliver in lung, colorectal, and other cancers driven by the same mutations, where today's treatments fall short.

M&A optionality just moved into the money

Merck was reportedly in talks to acquire Revolution Medicines at up to $32bn earlier in 2025 before walking away on valuation. That ceiling will now look cheap. With de-risked Phase 3 data in hand, Revolution Medicines becomes the most coveted late-stage oncology asset in the industry, at a time when Big Pharma is staring down a cliff of $200bn+ in upcoming patent expirations through 2028. Merck, Bristol, Pfizer, and Roche all have obvious strategic rationale to bid. At current levels ($27bn market cap), any credible takeout would likely be announced at a price north of $40bn, making it potentially the most expensive pre-revenue biotech buyout ever.

Fully funded = negotiating leverage

The $2bn raise doesn't just fund operations; it changes the M&A calculus. A fully-capitalized Revolution Medicines can walk away from an underwhelming bid. Pre-raise, the company was burning ~$1.1bn/year against ~$2bn in cash; any hostile or opportunistic offer had leverage. Post-raise, Revolution Medicines can run its own clinical and commercial playbook, extracting maximum value from the platform before (or without) selling.

The 2026 opex guide ($1.6-1.7bn) is massive but justified

Bears will point to the scale of spending. Eight Phase 3 trials is an unprecedented late-stage build for any single-asset company. But the Royalty Pharma deal, the $2bn raise, and the non-dilutive priority voucher credibility give Revolution Medicines the ability to run this playbook without returning to the capital markets for years. This is a company deliberately building a multi-asset oncology franchise, not a one-drug story.

Next catalyst: AACR 2026 (April 17-22)

The next test is just days away. At the AACR conference in San Diego (April 17–22), Revolution Medicines will present nine new datasets. Two stand out: on April 21, first-line data on daraxonrasib combined with chemotherapy, meaning the drug is used as a first treatment rather than after chemo has failed. And Phase 1 data on zoldonrasib, a sister drug targeting a different KRAS mutation, in lung cancer.

The stakes are simple. If daraxonrasib works as a first-line treatment, it stops being a single drug for one disease and becomes the foundation of an entire cancer franchise.

Our Takeaway

For four years, the narrative on biotech has been relentless: capital has fled, the XBI has underperformed, and generalists have concluded the sector is uninvestable outside of weight-loss drugs, and even there, Novo Nordisk's stock performance begs to differ. This week broke that narrative. A clinical-stage oncology company with zero product revenue priced a $2bn follow-on in 48 hours, at a 40% conversion premium, with demand exceeding supply by a factor of two.

For thematic biotech investors, the message is clear: breakthrough therapies still attract breakthrough capital. The next Revolution Medicines is out there, hiding in a Phase 2 readout nobody is paying attention to yet. That is where the real work is. 

Life-changing medicine remains one of the most powerful magnets for capital in the global economy. Even in a world obsessed with AI, the ability to keep someone alive for an extra year when nothing else could is still, in every sense of the word, priceless.